Inhibition of rat lung ACE at 38 ug/ml relative to control
|
Rattus norvegicus
|
0.0
%
|
|
Inhibition of rat lung ACE at 56 ug/ml relative to control
|
Rattus norvegicus
|
0.0
%
|
|
Inhibition of rat lung ACE at 75 ug/ml relative to control
|
Rattus norvegicus
|
9.0
%
|
|
Inhibition of rat lung ACE at 113 ug/ml relative to control
|
Rattus norvegicus
|
3.0
%
|
|
Inhibition of rat lung ACE at 150 ug/ml relative to control
|
Rattus norvegicus
|
19.0
%
|
|
Inhibition of rat lung ACE at 225 ug/ml relative to control
|
Rattus norvegicus
|
19.0
%
|
|
Inhibition of rat lung ACE at 300 ug/ml relative to control
|
Rattus norvegicus
|
133.0
%
|
|
Antiprotozoal activity against Entamoeba histolytica HM-1:IMSS trophozoites after 48 hrs by MTT/PMS assay
|
Entamoeba histolytica HM-1:IMSS
|
14.7
ug.mL-1
|
|
Antiprotozoal activity against Giardia lamblia IMSS:0989:1 after 48 hrs by MTT/PMS assay
|
Giardia intestinalis
|
87.3
ug.mL-1
|
|
Antioxidant activity assessed as DPPH free radical scavenging activity relative to control
|
None
|
16.6
ug.mL-1
|
|
Antioxidant activity assessed as superoxide anion scavenging activity by xanthine oxidase oxidation system relative to control
|
None
|
3.4
ug.mL-1
|
|
Antioxidant activity assessed as inhibition of 2,2'-azobis(2-amidinopropane)dihydrochloride-induced lipid peroxidation at 3.125 ug/ml by ferric thiocyanate system relative to control
|
None
|
49.9
%
|
|
Inhibition of TPA-induced EBV-early antigen activation in human Raji cells relative to TPA
|
Human herpesvirus 4
|
570.0
molar ratio
|
|
Antiviral activity against RSV Long in MDCK cells assessed as inhibition of virus-induced cytopathic effect
|
Respiratory syncytial virus
|
5.9
ug.mL-1
|
|
Cytotoxicity against MDCK cells
|
Canis lupus familiaris
|
23.4
ug.mL-1
|
|
Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
|
Human parainfluenza virus 3
|
23.4
ug.mL-1
|
|
Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
|
Influenza A virus
|
500.0
ug.mL-1
|
|
Inhibition of COX2 at 2.5 ug/mL
|
None
|
25.0
%
|
|
Antioxidant activity assessed as DPPH radical scavenging activity after 10 mins
|
None
|
20.4
ug.mL-1
|
|
Cytotoxicity against human Jurkat T cells after 36 hrs by MTT assay
|
Homo sapiens
|
100.0
ug.mL-1
|
|
Inhibition of Hepatitic C virus NS3/4A protease by FRET assay
|
Hepatitis C virus
|
10.0
ug.mL-1
|
|
Inhibition of electric eel AChE at 2 mg/ml by Ellman's method
|
Electrophorus electricus
|
0.12
%
|
|
Inhibition of horse BChE at 2 mg/ml by Ellman's method
|
Equus caballus
|
2.54
%
|
|
Antioxidant activity assessed as inhibition of DPPH radical production after 30 min by microplate assay
|
None
|
24.02
ug.mL-1
|
|
Antioxidant activity assessed as inhibition of DPPH radical production at 54.05 ug/ml after 30 min by microplate assay
|
None
|
86.09
%
|
|
Inhibition ofRattus norvegicus alpha-glucosidase isolated from intestine using PNPG as substrate at 0.02 uM incubated for 15 min prior to substrate addition measured after 15 min by spectrophotometric analysis
|
Rattus norvegicus
|
50.0
%
|
|
Inhibition of alpha-glucosidase (unknown origin) using PNPG as substrate at 0.02 uM incubated for 15 min prior to substrate addition measured after 15 min by spectrophotometric analysis
|
Homo sapiens
|
14.38
%
|
|
Inhibition of tyrosinase (unknown origin) using L-DOPA substrate at 1000 uM
|
Homo sapiens
|
54.55
%
|
|
Inhibition of tyrosinase (unknown origin) using L-DOPA substrate at 100 uM
|
Homo sapiens
|
40.59
%
|
|
Inhibition of tyrosinase (unknown origin) using L-DOPA substrate at 10 uM
|
Homo sapiens
|
0.0
%
|
|
Inhibition of PTP1B (unknown origin) using p-nitrophenyl phosphate as substrate at 100 uM
|
Homo sapiens
|
50.0
%
|
|
Inhibition of TRAP activity in RANKL-induced Balb/c mouse RAW264.7 cells at 10 uM after 1 hr by ELISA relative to control
|
Mus musculus
|
82.9
%
|
|
Inhibition of TRAP activity in Balb/c mouse RAW264.7 cells at 10 uM after 1 hr by ELISA relative to control
|
Mus musculus
|
168.48
%
|
|
Inhibition of TRAP activity in RANKL-induced Balb/c mouse RAW264.7 cells at 1 uM after 1 hr by ELISA relative to control
|
Mus musculus
|
76.57
%
|
|
Inhibition of TRAP activity in Balb/c mouse RAW264.7 cells at 1 uM after 1 hr by ELISA relative to control
|
Mus musculus
|
155.6
%
|
|
Inhibition of sEH (unknown origin) assessed as substrate PHOME hydrolysis at 25 uM after 1 hr by fluorescence method
|
Homo sapiens
|
40.0
%
|
|
Inhibition of porcine pancreatic lipase using p-nitrophenylbutyrate as substrate assessed as formation of p-nitrophenol at 100 uM preincubated for 15 mins followed by substrate addition measured after 15 mins relative to control
|
Sus scrofa
|
12.6
%
|
|
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 1 uM after 72 hrs by microplate reader analysis relative to control
|
Mus musculus
|
16.7
%
|
|
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 3 uM after 72 hrs by microplate reader analysis relative to control
|
Mus musculus
|
33.2
%
|
|
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 10 uM after 72 hrs by microplate reader analysis relative to control
|
Mus musculus
|
20.7
%
|
|
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 30 uM after 72 hrs by microplate reader analysis relative to control
|
Mus musculus
|
23.2
%
|
|
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 100 uM after 72 hrs by microplate reader analysis relative to control
|
Mus musculus
|
20.7
%
|
|
Inhibition of mushroom tyrosinase using L-DOPA as substrate assessed as dopaquinone production at 10 uM after 5 mins by microplate reader analysis relative to control
|
Agaricus bisporus
|
4.4
%
|
|
Inhibition of mushroom tyrosinase using L-DOPA as substrate assessed as dopaquinone production at 100 uM after 5 mins by microplate reader analysis relative to control
|
Agaricus bisporus
|
5.0
%
|
|
Inhibition of plasmin (unknown origin) at 100 uM after 18 hrs by arianor mahogany dye-based fibrin plate assay relative to control
|
Homo sapiens
|
-2.5
%
|
|
Anti-platelet activity in rat platelet rich plasma assessed as inhibition of ADP and calcium-induced platelet aggregation at 100 uM pre-incubated at 37 degC for 10 mins and measured 30 mins after ADP and calcium addition
|
Rattus norvegicus
|
36.24
%
|
|
Inhibition of alpha-amylase (unknown origin) relative to control
|
Homo sapiens
|
12.2
%
|
|
Inhibition of human recombinant carbonic anhydrase 4 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay
|
Homo sapiens
|
75.7
nM
|
|
Inhibition of human recombinant carbonic anhydrase 7 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay
|
Homo sapiens
|
3.8
nM
|
|
Inhibition of human recombinant carbonic anhydrase 12 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay
|
Homo sapiens
|
52.1
nM
|
|
Inhibition of human recombinant carbonic anhydrase 2
|
Homo sapiens
|
410.0
nM
|
|
Inhibition of human recombinant carbonic anhydrase 12
|
Homo sapiens
|
170.0
nM
|
|
Inhibition of Trichomonas vaginalis adenosine-guanosine preferring ribohydrolase after 40 mins
|
Trichomonas vaginalis
|
300.0
nM
|
|
Inhibition of Trichomonas vaginalis adenosine-guanosine preferring ribohydrolase after 40 mins in presence of 0.01% triton X-100
|
Trichomonas vaginalis
|
900.0
nM
|
|
Antileishmanial activity against amastigote Leishmania amazonensis
|
Leishmania amazonensis
|
0.78
ug.mL-1
|
|
Antichlamydial activity against Chlamydia pneumoniae K7 infected in HL cells assessed as chlamydial inhibition at 50 uM after 70 hrs by fluorescent microscopic analysis
|
Chlamydia pneumoniae
|
38.0
%
|
|
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600)
|
Staphylococcus aureus subsp. aureus
|
18.79
%
|
|
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600)
|
Escherichia coli
|
-1.78
%
|
|
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600)
|
Klebsiella pneumoniae
|
10.08
%
|
|
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600)
|
Pseudomonas aeruginosa
|
60.53
%
|
|
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600
|
Acinetobacter baumannii
|
25.15
%
|
|
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630
|
Candida albicans
|
1.9
%
|
|
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570)
|
Cryptococcus neoformans
|
3.22
%
|
|
Inhibition of LSD1 (unknown origin) by fluorescence assay
|
Homo sapiens
|
950.0
nM
|
|
Inhibition of PCSK9 mRNA expression in human HuH7 cells at 2 uM after 24 hrs by qRT-PCR assay relative to control
|
Homo sapiens
|
20.0
%
|
|
Inhibition of ATP synthase in Escherichia coli relative to control
|
Escherichia coli
|
40.0
%
|
|
Hypolipidemic activity against oleic acid/palmitic acid-induced hyperlipidemia in human HepG2 cells assessed as reduction in triglycerides content relative to control group
|
Homo sapiens
|
30.42
%
|
|